COLUMBUS, Ohio / Apr 03, 2025 / Business Wire / Mettler-Toledo International Inc. (NYSE: MTD) announced it will release its first quarter 2025 financial results after the market close on Thursday, May 1, 2025. The Company will host a conference call the following morning at 8:30 a.m. Eastern Time to discuss the results. To listen to the live audio webcast of the call, visit Events and Presentations on the Investor section of the Company’s website, investor.mt.com.
METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit www.mt.com.
Last Trade: | US$1,321.06 |
Daily Change: | 8.72 0.66 |
Daily Volume: | 32,645 |
Market Cap: | US$27.210B |
August 04, 2025 November 07, 2024 August 01, 2024 May 25, 2023 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load